Equities

Catalent Inc

Catalent Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)59.66
  • Today's Change0.66 / 1.12%
  • Shares traded1.19m
  • 1 Year change+49.75%
  • Beta1.1480
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform0
Hold9
Sell0
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for Catalent Inc have a median target of 63.50, with a high estimate of 63.50 and a low estimate of 63.00. The median estimate represents a 6.44% increase from the last price of 59.66.
High6.4%63.50
Med6.4%63.50
Low5.6%63.00

Earnings history & estimates in USD

On Nov 05, 2024, Catalent Inc reported 1st quarter 2025 losses of -0.13 per share.
The next earnings announcement is expected on Feb 07, 2025.
Average growth rate-32.50%
Catalent Inc reported annual 2024 earnings of 0.25 per share on Aug 29, 2024.
Average growth rate-19.31%
More ▼

Revenue history & estimates in USD

Catalent, Inc. had 1st quarter 2025 revenues of 1.02bn. This missed the 1.06bn consensus estimate of the 6 analysts following the company. This was 4.18% above the prior year's 1st quarter results.
Average growth rate+2.23%
Catalent, Inc. had revenues for the full year 2024 of 4.38bn. This was 2.46% above the prior year's results.
Average growth rate+10.25%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.